🚀 Sign up Free for Public Company Valuation & Insights!
Sign up for free to get access to the best public company valuation and insights. Get started today and unlock the potential of your investments!
Sign up free Video Highlights
Novartis
-10.71%
Pharma / Pharmaceuticals and Healthcare
At a Glance | Core Facts | Company Due Diligence: | Industry Due Diligence: | Competitors | Stock Swings | News | Income | Balance | Cash Flow | Growth | Enterprise | Ratios | Metrics | Dividends | Risks | SWOT | Porter's Five Forces | PEST | Score Positive | Clusters | Reports | Web1. Patent Expiration: The expiration of patents on key drugs is a major risk for Novartis, as it could lead to a loss of revenue when generics enter the market and reduce prices.
2. Competitive Pressure: Growing pressure from competitors could force Novartis to reduce prices, leading to lower revenues and profits.
3. Litigation Risk: Novartis has been and continues to be involved in various lawsuits, some of which have resulted in financial settlements.
4. Macroeconomic Risk: Novartis is dependent on the global economy and is subject to risk from fluctuations in foreign exchange rates, commodity prices, and other macroeconomic factors.
5. Strategic Risk: Strategic decisions can result in huge rewards, but when they are wrong, they can have long-term negative repercussions.
Wait! There's more — sign up for free or log in